Physician profile
Kyle Michael
NPI 1063264752
$1,493.63
in general payments reported to CMS, 2019-2025
11 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $277 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.65 |
| Education | $172.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $354.27 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $222.63 | 2024-2025 | Nucala, Arexvy |
| Astellas Pharma US INC | $172.98 | 2025 | |
| Novo Nordisk INC | $160.68 | 2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $124.74 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $118.58 | 2025 | Inspire |
| Vertex Pharmaceuticals Incorporated | $114.07 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.01 | 2025 | |
| Lilly USA, LLC | $56.95 | 2025 | Zepbound |
| Tg Therapeutics, INC. | $48.91 | 2024 | |
| Pfizer INC. | $19.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.